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Dr Scott M. Bradley (Charleston, SC). That was an excellent
presentation on a topic that is clearly a challenge to everyone in
the room. I thought that the information on the relative importance
of low birth weight versus prematurity was particularly interesting,
as was the growth velocity that can be expected in these low-birth-
weight babies. I do have a couple of questions about the ways in
which you have chosen to analyze your data.
The first question has to do with the 2 groups, which you call
‘‘early’’ and ‘‘delayed.’’ This differentiation was based on your ret-
rospective assessment of the goal of the management team at the
time that the patient presented. I commend you for going through
all of those charts and figuring that out. Nonetheless, some of the
patients in the delayed group underwent intervention within the
first 1 to 2 weeks of life, which would not be considered very
delayed and certainly not long enough to expect much growth.
Do you have any information for us on the ages at intervention
in the early group and whether there was overlap with what you
call the delayed group?
Dr Hickey. Thank you very much, Dr Bradley, for your
questions.
In terms of the categorization of patients, it is very difficult ret-
rospectively and it would be great to do a prospective study, but
that is simply impractical or impossible.
Rather than opt for procedure-based categories, for example,
palliation or repair, wewanted to categorize in terms of completely
deviating from the strategy. As best as I can, I think I have done
that.
In terms of the ages of the 2 groups, patients in the early group
were generally all intervened on the next available appropriate
clinical slot in the neonatal period after presenting, so within the
first 2 to 3 weeks after birth, whereas the mean age at intervention
for the delayed group was on average about 8 weeks later. Of
course, we had a number of deaths even within 1 to 2 weeks of
being delayed.
Dr Bradley. It appears that if the early group was intervened on
within the first 2 to 3 weeks after birth, there was significant over-
lap between the early and the delayed groups. That would probably
be good information to put in the article.
Would it have been more clear-cut to simply analyze the pa-
tients on the basis of their age at intervention as either a continuous
or a categorical variable, rather than trying to look back and134 The Journal of Thoracic and Cardiovascular Surgdetermine the intentions of the team at the time, which was up
to 10 years ago?
Dr Hickey. Certainly you can look at age at intervention, and
we have done so in several other series. We know age at interven-
tion is a very important variable. We specifically wanted to go back
to the decision-making algorithm from the outset and make a deci-
sion-making analysis rather than just a risk-hazard-based analysis
in retrospect.
Dr Bradley. I want to ask about a topic that you mentioned-the
type of interventions in the 2 groups. Many of these patients were
candidates for more than 1 intervention, for example, in tetralogy
of Fallot, complete repair versus palliation with a shunt, in hypo-
plastic left heart syndrome, Norwood versus hybrid procedure.
I assume that some of your patients underwent catheterization in-
terventions, for example, balloon septostomy in patients with
transposition and balloon aortic valvotomy in patients with aortic
stenosis. Other catheterization interventions, while not routine,
could be considered in selected patients, for example, stenting
the outflow tract or the ductus in tetralogy or pulmonary atresia.
Do you have any analysis of the breakdown of the types of inter-
vention in your 2 groups: complete repair versus palliation versus
catheterization laboratory?
Dr Hickey. It was our hope and intention from the outset that
we might end up with some homogeneous patient groups, either
in terms of diagnosis or in terms of interventional strategy, that
we could then compare. It was very clear from the outset, though,
that that was not going to be the case. This is actually quite an un-
common problem if you consider 80 patients over 10 years. We
have a catchment area of about 13 million at Toronto. This is ac-
tually quite an unusual dilemma, although it is one we are all
very familiar with. That is why we have such a heterogeneous
bunch. Therefore, it is very difficult to compare one specific inter-
ventional strategy versus another. We have not been able to do that.
In terms of the range of options for each child, that exists for
a normal-birth-weight child. Even for a child of normal birth
weight with tetralogy or truncus or whatever, there can be different
management strategies. We were only interested if we completely
deviated and did something different because of the very low birth
weight.
Dr Bradley. Fair enough. I think it would be useful to include
some information on whether you are talking about complete re-
pairs or palliation, especially in the early group. Although you
did factor patient diagnosis into your risk-adjustment analyses,
I would think you could enter complete repair versus palliation
into that analysis as well.
One final question: You have given us some valuable informa-
tion on the growth velocity that we can actually expect in these
low-birth-weight patients if we do decide to take a wait-and-feed
approach. Growth is generally more effective on enteral feeding
than on total parenteral nutrition. However, many practitioners
are reluctant to enterally feed a premature, low-birth-weight
baby, especially if the infant is receiving a prostaglandin infusion.
Can you tell us how the babies in your delayed group were ap-
proached in terms of feeding to achieve growth, from your review
of charts, or what your approach would be now, particularly in
a baby who is receiving a prostaglandin infusion?
Dr Hickey. Unfortunately, I cannot elaborate much on that in-
formation because we did not have those data. Nor am I, by anyery c January 2012
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Dstretch of the imagination, an expert on nutrition in these small in-
fants. Nevertheless, in our intensive care unit we aggressively try
to enterally feed all our infants unless there is a strong reason to
do otherwise. Obviously, we use fortified feeds with dietician
advice and all that sort of thing.
In terms of the difference between the growth rates, I was most
struck by the difference, especially the infants with coarctation,
which seemed to grow at a very high level of statistical significance
at a very low rate. That to us suggests that of all the groups, patients
with coarctation are maybe the ones on whom we should operate
early. Indeed, that iswhatwedonow routinely, down to1.4 to 1.5kg.
I have just one final comment about your previous comments
about palliation: At Sick Kids we have a very high threshold for
palliative strategies. In the mid-1990s we switched, for example,
from using any shunts for patients with tetralogy; it is rare, in
fact, that we use bands or shunts in children now. Indeed, in this
series they were very infrequent occurrences.
The data on long-term prostaglandin therapy, especially, is
encouraging us to now explore other catheter-based approaches
that can be used instead of long-term prostaglandin, especially
subxiphoid approaches for tiny infants.
Dr Bradley. Fair enough. I think it is a very nice study. It is
a relatively large group of patients with these issues. If you could
provide some of this additional information in the article, it would
be of interest to the readers.
Dr V. Mohan Reddy (Stanford, Calif). Dr Hickey, I would like
to ask you a few questions. I know you looked at a lot of risk
factors, but did you look at patients who were dependent for a pro-
longed period for mechanical ventilation or prostaglandins versus
patients who are not dependent?
Dr Hickey. As subgroups, no, but they were both included as
risk factors. We had acquired respiratory morbidity as a risk factor
from the outset as baseline.
Dr Reddy. From the data, I could see that patients whose treat-
ment was delayed had a significantly higher incidence of compli-
cations and there was also some mortality.
Dr Hickey. That is true.
Dr Reddy. But overall, there was no difference. What do you
think accounted for the mortality in the early group to equalize it?
Dr Hickey. Intuitively, the assumption is that intervening in
very small children is of elevated risk. We assume that the greater
morbidity and mortality burden is in some way outweighed by the
risk of intervening on these very small children.
Equally, we fully acknowledge that there are important differ-
ences within the patient groups, which is why we have tried to
look at it in multiple different ways; but we still are not seeing
an important difference between the 2 strategies.
Dr Reddy. Most likely, it could be technical. As with all tech-
nical operations, we gradually get better when we do the operation
over time. I can assure you that even though the patient’s weight
increases from 1.5 kg to 2 kg or 2.2 kg, the heart is not going to
be much bigger than 10 mg or 20 mg. Thus, I do not think it tech-
nically makes a huge difference. I think it is more in the mind than
in actually doing the operation.
Dr Hickey. In terms of the risk of actually performing the op-
eration, I agree, the technical aspects are very valid. Furthermore,
certainly most here will know that your group at Stanford has man-
aged to mitigate some of these issues, perhaps because of yourThe Journal of Thoracic and Caexperience with operating on fetal animals. You are much more at-
tuned to operate on the infant weighing 1.1 to 1.2 kg. Those are
technical hurdles that others would have to overcome if they adopt
that aggressive early approach.
However, certainly these smaller children are also physiologi-
cally different. There are immunologic risk factors, there are nutri-
tion factors, they are much more prone to other complications,
cerebral bleeds, that sort of thing, and so there are differences.
There is just one thing about this weight that I find fascinating.
I have done subanalyses looking at the normal-birth-weight range,
and even within the normal-birth-weight range, birth weight is
a very strong determinant of risk, which is a very curious and in-
teresting fact.
Dr Reddy. I think this is very important information to have
available. However, I personally think that the patient should be in-
dividualized, not necessarily bunched into 1 of 2 categories, early
and late or left-sided versus right-sided lesions. If the patients are
dependent on a ventilator or requiring prolonged prostaglandins in
the infusions, then wewould generally tend to intervene. However,
if the patient can be extubated and can be fed normally or can be
taken off prostaglandin, I think the operation can certainly be
delayed.
Dr Hickey.Wewould agree with you. We do not think our data
can strongly advocate for one approach or the other, so we agree
that the approach needs to be individualized. We also will inter-
vene very early on very small patients with truncus or coarctation
if we think that that child clinically is of acceptable risk to undergo
an operation early. However, we are also reassured that if we
choose to take a delayed approach, we are not taking on an exces-
sive morbidity risk.
Dr Reddy. I also think more recent data suggest that the gesta-
tional age may have an impact on the neurologic injury and the
brain maturation. That might be a more common factor for us to
delay surgery in these patients, if we can safely.
DrHickey.Certainly. Dr Gaynor’s group has done a lot of work
showing very nicely that babies born at term with certain lesions
are developmentally very immature, and that is a strong determi-
nant of neurologic injury. Therefore, although we have focused
on survival as the end point, we have not taken into account the
morbidity burden in the long-term with either strategy, and that
may be just as important.
DrReddy.One last question. Do you have any plans to do a pro-
spective study in this regard?
Dr Hickey. I think the numbers that we have generated, 80 over
10 years from 1600 patients, really preclude that.
Dr Frank A. Pigula (Boston, Mass).My question is whether it
is really fair to equate weight gain with growth in children who are
receiving prostaglandins and are intubated with various means of
nutritional support. I am not sure that they are really the same thing
in those patients.
My other comment is that in analysis of our unit with these pa-
tients, their gestational age has been more important than their
size. We can operate on very small patients, but we cannot make
them older when we operate on them. Could you please address
the age versus size issue?
Dr Hickey. When we pitched prematurity, that is, gestational
age to birth weight, consistently birth weight was the more reliable
determinant. That is because prematurity, although very important,rdiovascular Surgery c Volume 143, Number 1 135
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Das our data showed, is important because of the whole host of prob-
lems that come with it—certain lesions, certain other comorbid-
ities, certain genetic syndromes, and such like. That’s what the
data were telling us was accounting for the risk of prematurity.
Birth weight per se is a more reliable determinant as an indepen-
dent risk factor for death.
Dr Pigula. That is interesting. That is a little bit counter to what
we have seen in our group.
Dr Christian Pizarro (Wilmington, Del). That was a beautiful
job. I am unclear about how patients were fed and how the choice
was made. I saw you encountered a lot of gastrointestinal compli-
cations. A common problem we all face is that we see a tiny little
baby and want to use enteral feeds, but we are hesitant, particularly
in someone who has a shunt at the arterial level, such as an infant136 The Journal of Thoracic and Cardiovascular Surgwith truncus or hypoplastic left heart syndrome. What was the
choice regarding feeding or nutrition in those patients, and could
that be in any way related to the speed of weight gain?
DrHickey.That is entirely possible. I do not have all the data on
the mechanisms of which patients were fed. Certainly gastrointes-
tinal complications were common, as you expect in these very
small children. We try to feed them enterally if at all possible to
avoid necrotizing enterocolitis and other complications, but I do
not have the specifics of that information.
In terms of weight gain, I am not sure what actually gave rise to
the differences that we saw in weight gain. However, the category
that really stuck out was patients with coarctation. They are not
normally the infants who have all the other comorbidities, and
yet their weight gain was very poor to a high level of significance.ery c January 2012
